Washington, DC (PRWEB) September 6, 2007
Cardiocore, a premier centralized cardiac testing laboratory, expanded its service offering today to include centralized echocardiographic analyses. These services support the needs of Cardiocore's growing client base of oncology, cardiovascular and other drug developers who use echocardiography to study cardiac safety and efficacy.
Cardiocore's echocardiography service is managed by its Vice President of Medical Operations, Dr. Polina Voloshko, whose oncology and cardiovascular protocol expertise has developed over 22 years as a cardiologist and clinical researcher. Before coming to Cardiocore, Dr. Voloshko directed centralized echocardiography services for Gentiae and the esteemed Ischemia Research and Education Foundation.
Dr. Voloshko is supported by Nelson Schiller, MD, FACC, an international thought leader in echocardiography. In addition to his role as a Senior Medical Consultant for Cardiocore, Dr. Schiller is a Professor at the University of California San Francisco Division of Cardiology and the Director of Echocardiography Research at the San Francisco Veterans Affairs Medical Center.
Dr. Voloshko's team also includes 16 board-certified cardiologists and a team of professional echo analysts who have performed centralized echocardiographic measurements and calculations for both biotech and large pharmaceutical companies.
In response to Cardiocore's announcement, the Associate Director Global Development for a Top 5 pharmaceutical company said, "The combination of Dr. Polina Voloshko's experienced echo analysts, Dr. Larry Satin's top-notch cardiologists and Jennifer Cotteleer's sophisticated data management systems makes Cardiocore the perfect echocardiography team." She continued, "Starting today, Cardiocore will be our preferred echocardiography provider."
"An increasing number of sponsors are using echocardiography in drug trials to examine changes to the heart's structural health and functionality," said Dr. Voloshko, adding, "this type of analysis is now an essential part of cardiac safety and efficacy assessments for many oncology, cardiovascular, diabetes, obesity and metabolic diseases."
In addition to protocol consulting, Cardiocore's echocardiography analyses include ejection fraction, ejection time, cardiac output, fractional shortening, left ventricular volumes, left ventricular mass, and various Doppler, 2-D and M-Mode calculations based on protocol requirements. Services also include board-certified cardiologist interpretation and state-of-the-art echocardiographic data management.
At Cardiocore's launch ceremony, Chief Medical Officer, Lawrence Satin, MD, FACC said, "We have built our scientific consulting, ECG and Holter offerings on the principle that best-in-class science leads to a best-in-class business, and we have approached echocardiography in exactly the same way. Our current and future echo customers can always rely on our accessible and thoughtful expertise."
Cardiocore has provided superior centralized cardiac testing services to the pharmaceutical industry for 14 years. Services include centralized electrocardiographic (ECG) analysis, Holter monitoring, echocardiography, statistical analysis and consulting services such as protocol design. The company is experienced in design and implementation of Thorough QT Trials and cardiac safety and efficacy testing in Phase I, II and III clinical trials. These services are supported by the company's CardioCorrect® system featuring the proprietary HolterGateway™ and CardioPortal™. Cardiocore's U.S. headquarters is located in Bethesda, Maryland, its West Coast office is located in San Francisco, California, and its European subsidiary, Cardiocore Limited, is located in London, England.